NTRB: Tiny Float Emerging Pharma Play Pulls Back to Trendline Support
img

info@bullishguru.com 1(844)30-STOCK
To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
Our new pick is NTRB
 

 

Good Afternoon Traders!

New Pick:  Nutriband Inc. (OTCMKTS: NTRB)

We love a good pharma story that can cook on a small float. That’s why we are putting NTRB in front of you right now. 

The company is moving and shaking in the space with a corner on the transdermal patch theme, and just made a play to gobble up Carmel Biosciences, a pharmaceutical company that addresses critical needs in the cardiovascular and metabolic therapies space and just got great news from the FDA.

NTRB trades on a tiny float (under 2.5M shares) and finally pulled back to test trendline support and give us a chance to possibly climb on the elevator before it potentially heads up to the next floor. Just a simple flash back up to test recent highs could represent as much as 80% on the upside. 

So it’s worth having a closer look.

Symbol:  NTRB

Company:  Nutriband Inc.

Quote:  http://finance.yahoo.com/q?s=NTRB

Latest News:  http://finance.yahoo.com/q/h?s=NTRB+Headlines

NTRB.Chart
Key Points:

  • NTRB trades on a very tight float of just 2.3 million shares, so any influx of new interest could potentially send this stock into orbit.
  • NTRB is logging RSI prints under 40 right now, pointing to a massively oversold stock now looking to potentially spring back the other way.
  • NTRB is currently testing key trendline support as liquidity rises in this newly discovered pharma play.
  • NTRB just signed on to swallow Carmel Biosciences, new FDA approval in tow.
  • NTRB also just signed an exclusive 20-year, $90 million distribution deal with a Korean distributor to penetrate Asian markets.

Nutriband Inc. (OTCMKTS: NTRB) is a very speculative play that has the potential to be powered by its announcement out last month that it has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies.  

Why could this be such a big deal? Because Carmel Biosciences received FDA approval a few months ago for PREXXARTAN, the first and only approved oral liquid dosage form of the angiotensin receptor blocker (ARB) valsartan in the United States.

Nutriband plans to complete the deal, valued at approximately $3.8 million, through payment of 450,000 restricted common shares of the Company’s stock. Remember: this stock is just toting around a little over 2 million shares on the float. That means that any sort of extra attention has the potential to push the stock like a feather caught in an updraft.

NTRB is a Pharmaceutical and Health company with a specific focus on Transdermal and Topical technologies.

Nutriband is a pharma play based in Orlando. According to company materials, “Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.”

The company operates primarily in the health supplement market. Its product line consists of an energy patch line, a weight management patch line, a multivitamin patch line, a children’s multivitamin patch line, an amino acid patch line, an anti-wrinkle patch line, an insect repellant patch line, a detox patch line, a PMS patch line, a sleep patch line, and a nausea and motion sickness patch line.

According to the deal release, “PREXXARTAN (valsartan oral solution) is indicated for treatment of hypertension in adults and children six years and older. PREXXARTAN is also indicated for use as therapy for the treatment of heart failure (NYHA class II-IV). Additionally, PREXXARTAN has also been indicated for stable left ventricular failure or left ventricular dysfunction after myocardial infarction.”

“The Carmel Biosciences team combines a deep understanding of lipid biochemistry and clinical expertise in the cardiovascular and metabolic space,” stated Gareth Sheridan, CEO of Nutriband. “Carmel’s focus in the reformulation of drugs with a high degree of safety and efficacy allows improved access to patients who have difficulty swallowing tablets or capsules and provides enhanced usage of these widely acclaimed products.”

Just before that, the company announced that it had signed an exclusive 20-year, $90 million distribution agreement for its transdermal consumer product lines with Best Choice Inc., a Korean consumer products distributor with a 20-year history of working with major chain retailers, including Costco and Lotte Department Stores.  

As for the technical side, the stock has been charging up the charts in a nice steady trend basically all year. If you’ve been looking for a pullback to get involved, right now is the time, which is why we are bringing this one to your attention. 

We are testing trendline support right now. And with just a tiny 2.3 million shares rattling around on the float, if this news spreads and the stock gets some traction, a major squeeze is not out of the question here.

About NTRB

NTRB (Nutriband Inc.) is a Pharmaceutical and Health company with a specific focus on Transdermal and Topical technologies.

Nutriband is a pharma play based in Orlando. According to company materials, “Unlike traditional health product companies, Nutriband found its start by spotting and targeting a gross and virtually unexplored niche in the supplement market through its method of ingredient delivery. All Nutriband products are based around the science of transdermal / Topical technologies.”

The company operates primarily in the health supplement market. Its product line consists of an energy patch line, a weight management patch line, a multivitamin patch line, a children’s multivitamin patch line, an amino acid patch line, an anti-wrinkle patch line, an insect repellant patch line, a detox patch line, a PMS patch line, a sleep patch line, and a nausea and motion sickness patch line. 

Nutriband Inc. was incorporated in 2016 and is headquartered in Oviedo, Florida.

 
DISCLAIMER:

Please Read carefully before buying any stock. BullishGuru.com has a no tolerance spam policy, we will not sell or redistribute your email to any third party.

If applicable, please, also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members. Verify all claims and do your own due diligence. BullishGuru.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Bullishguru.com  is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. BullishGuru.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies.

The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

In order to be in full compliance with the Securities Act of 1933, Section 17(b), BullishGuru.com is owned and operated by BullishGuru.com. Neither BullishGuru.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from the use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this web site or e-mail and any contents. Since BullishGuru.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in BullishGuru.com statements and opinions and such statements and opinions cannot be considered independent. BullishGuru.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. BullishGuru.com services are often paid for using free-trading shares. BullishGuru.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

In considering whether to trade, you should be aware of the following points:

The national securities markets are extremely efficient and competitive. Successful trading typically requires skill and discipline as well as experience and knowledge of the capital markets. There is no guarantee that you will be successful in implementing your investment strategy. A substantial number of traders will not be successful. Moreover, changes in market structure and competitive conditions also may affect your continued success. Only risk capital should be used for trading. Market structure and competitive changes in the markets may cause formerly successful traders to become less successful. Trading can involve a volume of activity. Each trade generates a commission and the total commissions on such trading can be in excess of any earnings. Persons who are new to trading should strictly limit both the number of trades they do and the size of their trades to reduce the risk of large dollar losses during the learning process. Trading activity may result in losses that can exceed 100% of your initial capital. You are solely responsible for any losses in your account. Placing contingent orders, such as “stop-loss” or “stop-limit” orders, will not necessarily limit your losses to the intended amounts, since market conditions may make it impossible to execute such orders. Similarly, using “market orders” can be very risky, since large gaps can occur in price movements of active stocks. Under certain market conditions, you may find it difficult or impossible to liquidate a position quickly at a reasonable price. This can occur, for example, when the market for a stock suddenly drops, or if trading is halted due to recent news events or unusual trading activity. The more volatile a stock is, the greater the likelihood that problems may be encountered in executing a transaction. In addition to normal market risks, you may experience losses due to system failures. The firm and its clearing broker rely upon sophisticated computer software and hardware to execute transactions, which are subject to failure due to a variety of factors. Among other events, you may experience losses due to: system crashes during both peak and low volume periods; the loss of orders and, delayed, conflicting and inaccurate confirmations on orders or cancellations that you initiate. The use of any margin or leverage in an account can work against you as well as for you. Leverage can lead to large losses as well as gains. You may sustain a total loss of the initial margin funds and any additional funds that you deposit with your broker to establish or maintain a position, and you may incur losses beyond your initial investment. If the market moves against your position, you may be called upon to deposit a substantial amount of additional margin funds, on short notice, in order to maintain your position. If you do not provide the required funds within the time required, your position may be liquidated at a loss, and you will be liable for any resulting deficit in your account. You should consult your broker concerning the nature of the protections available to safeguard funds or property deposited in your account. ALL OF THE POINTS NOTED ABOVE APPLY TO BOTH STOCK AND OPTION TRADING OF DOMESTIC EQUITY SECURITIES. THE RISK OF DAY TRADING AND/OR OPTION TRADING MAY BE SUBSTANTIAL. THIS BRIEF STATEMENT CANNOT DISCLOSE ALL THE RISKS AND OTHER ASPECTS OF TRADING. ONLY RISK CAPITAL SHOULD BE USED FOR TRADING.

Neither any of the information, nor any opinion expressed anywhere in BullishGuru.com’s Web site, Content or services constitutes a solicitation or recommendation to purchase or sell a security, or an option on a security, or to provide investment/financial advice. Always verify information with your stockbroker or financial advisor before making a trade or acting on such information. We will not be liable for any errors or delays in the Content or any action taken based thereon.

BullishGuru.com (BG) is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of BG may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. The BG, the authors, the publisher, and all affiliates of BG assume no responsibility or liability for your trading and investment results. Factual statements on the BG’s website, or in its publications, are made as of the date stated and are subject to change without notice.

 

 It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by BG are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of BG’s products (collectively, the “Information”) are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on BG’s website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

Remember to do your own due diligence before getting into any stock . We are in the business of providing online advertisement for publicly traded companies. Any stock mentioned on our website tweets or social media accounts is for advertising purpose

Bullishguru has been compensated total of two thousand dollars by ALG financials to perform two day investors awareness advertisement  program on NTRB

Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners and the owners retain all legal rights. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is.

CR 2009- 2017, www.bullishguru.com. All rights reserved.

Subscribe To Our Daily Newsletter